Structure Therapeutics

What Structure Therapeutics does

Structure Therapeutics is a clinical-stage biopharmaceutical company developing oral small molecule therapeutics for chronic metabolic and cardiopulmonary diseases, with an initial focus on obesity. The company was founded in 2016 and is headquartered in South San Francisco, California, with a research and development center in Shanghai, China; it is publicly listed on NASDAQ under the ticker GPCR. Its core technology is a proprietary structure-based drug design platform that combines G-protein-coupled receptor (GPCR) structural biology, computational chemistry, and data science to design oral small molecules against the largest family of drug targets across multiple disease areas.

The company's pipeline is anchored by aleniglipron (also known as GSBR-1290), an oral small molecule GLP-1 receptor agonist that demonstrated up to 16.3% placebo-adjusted weight loss in the Phase 2 ACCESS II trial at 44 weeks with the 180mg dose and an overall discontinuation rate of 10.4%. Phase 3 initiation is planned for Q3 2026 with potential FDA approval targeted by 2029. The pipeline also includes ACCG-2671, an oral small molecule dual amylin and calcitonin receptor agonist in Phase 1; ACCG-3535, a preclinical dual amylin/calcitonin receptor agonist; and earlier-stage GIPR, GCGR, and GLP-1RA + Amylin combination programs. The platform was co-developed within Schrödinger's ecosystem, which retains approximately 6% equity in Structure.

Structure Therapeutics is pre-revenue and currently monetizes only through a non-exclusive patent licensing agreement with Roche/Genentech (CT-996 program) worth $100 million upfront plus low-single-digit royalties. Future revenue is expected to come from the sale of prescription oral obesity and metabolic disease medications upon regulatory approval, distributed through standard pharmaceutical wholesale and specialty pharmacy channels, targeting a global obesity population of more than 800 million patients and a total addressable market exceeding $100 billion. The company carries $1.4–1.5 billion in cash and investments as of early 2026 following a $747.5 million upsized public offering in December 2025, providing runway through 2028.

Name

Structure Therapeutics

Legal name

Structure Therapeutics, Inc.

Website

https://structuretx.com

Company type

Public

Founded year

2019

Operating status

Operating

Headcount range

101–250 employees

Short description

Structure Therapeutics is a clinical-stage biopharmaceutical company developing oral small molecule therapeutics for chronic metabolic and cardiopulmonary diseases, anchored by its GLP-1 agonist aleniglipron (Phase 2) for obesity and built on a structure-based drug design platform targeting GPCRs.

Ownership category

akta.pro rank

Product category

Obesity Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)

Keywords

• Oral small molecule therapeutics
• GPCR drug discovery
• Obesity treatment pipeline
• Structure-based drug design
• Metabolic disease medicines

Headquarters

HQ city

South San Francisco

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations

Revenue model

1. Pharmaceutical Product Sales: Structure Therapeutics is a pre-revenue clinical-stage biopharmaceutical company. Once products receive regulatory approval, the company plans to generate revenue through the sale of prescription medications, initially targeting the obesity and metabolic disease markets with oral small molecule GLP-1 and amylin receptor agonist therapeutics.

Go-to-market motion1 record

Marketing channels5 records

Core offering

Structure Therapeutics is a clinical-stage biopharmaceutical company that develops oral small molecule therapeutics targeting G-protein-coupled receptors (GPCRs) for chronic metabolic and cardiopulmonary diseases, with an initial focus on obesity. The company leverages a proprietary structure-based drug design platform to create oral, non-peptide alternatives to injectable biologic and peptide therapies, addressing scalability, cost, and administration challenges of current treatments.

Product overview

Structure Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of oral small molecule therapeutics for chronic metabolic and cardiopulmonary diseases, with an initial focus on obesity. The company's portfolio includes Aleniglipron (GSBR-1290), a GLP-1 receptor agonist in Phase 2 development showing up to 16.3% weight loss; ACCG-2671, a dual amylin and calcitonin receptor agonist in Phase 1; and ACCG-3535, a preclinical dual amylin/calcitonin receptor agonist. These candidates are designed as oral alternatives to injectable biologic and peptide therapies, leveraging the company's structure-based drug design platform targeting GPCRs to improve scalability and patient accessibility.

Differentiator

Problem solved

Functional benefit

Brands

• Aleniglipron: Oral small molecule GLP-1 receptor agonist for obesity treatment, currently in Phase 2 clinical trials showing up to 16.2% weight loss.
• ACCG-2671
• ACCG-3535
• GSBR-1290

Products and services

• Aleniglipron (GSBR-1290) An oral small molecule GLP-1 receptor agonist (GLP-1RA) for obesity treatment. Demonstrated up to 16.3% placebo-adjusted weight loss in Phase 2b ACCESS trials and positioned as a potential best-in-class oral GLP-1 therapy.
• ACCG-2671 An oral small molecule dual amylin and calcitonin receptor agonist (DACRA) for obesity treatment. Currently in Phase 1 clinical study evaluating safety, tolerability, and pharmacokinetics in healthy volunteers and individuals with obesity.
• ACCG-3535 A novel oral small molecule dual amylin and calcitonin receptor agonist for obesity treatment, in preclinical development stage.
• GIPR Program Discovery-stage oral small molecule program targeting the GIP receptor for obesity and metabolic disease treatment.
• GCGR Program Discovery-stage oral small molecule program targeting the glucagon receptor for obesity and metabolic disease treatment.
• GLP-1RA + Amylin Combination Combination therapy program combining an oral GLP-1 receptor agonist with an amylin receptor agonist for obesity treatment, in IND-enabling development.

Quantifiable outcome

• Up to 16.3% placebo-adjusted weight loss at 44 weeks with aleniglipron 180mg dose in Phase 2 ACCESS II trial
• +4 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Two partnerships are on record, tiered core.

• Roche/GenentechcoreOEM/ Whitelabel/ Licensing Partner · 5 January 2026Structure Therapeutics licensed patents to Roche for CT-996 (oral GLP-1 drug acquired through Carmot Therapeutics for $2.7 billion) in a deal worth $100 million upfront plus additional low-single-digit royalties on future net sales. The agreement protects Roche from potential patent infringement claims related to the drug, with Leerink Partners analysts noting this validates Structure's IP position in the oral GLP-1 space.
• Schrödinger (Co-founding Entity)coreStrategic or Co-development PartnerStructure Therapeutics was co-founded as part of Schrödinger's ecosystem of co-founded companies. Schrödinger holds approximately 6% equity in Structure and highlighted the company's Phase 2b data as a key milestone in its 2025 business update. Structure's structure-based drug discovery platform benefits from Schrödinger's computational molecular discovery capabilities.

Scale indicators16 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Terns Pharmaceuticals: Terns Pharmaceuticals is a clinical-stage biotech developing TERN-601, an oral small molecule GLP-1 receptor agonist for obesity. Terns is one of the closest direct competitors to Structure's aleniglipron, targeting the same oral small molecule GLP-1 niche with similar patient access and scalability advantages over injectables.
• Viking Therapeutics: Viking Therapeutics is a clinical-stage obesity-focused biotech with VK2735 (dual GLP-1/GIP injectable) showing strong weight loss in trials. While Viking's lead is injectable versus Structure's oral approach, both are mid-cap biotechs pursuing differentiated next-generation obesity therapeutics with similar competitive dynamics.

Broad incumbents

• Eli Lilly: Eli Lilly is the dominant incumbent in the GLP-1 obesity market with orforglipron (oral small molecule GLP-1 in late-stage trials) and retatrutide (28.3% weight loss in Phase 3). Lilly's massive commercial infrastructure, manufacturing scale, and capital make it Structure's most significant competitive threat and benchmark for oral GLP-1 efficacy.
• Roche/Genentech: Roche/Genentech acquired Carmot Therapeutics for $2.7B to access CT-996, an oral small molecule GLP-1, and subsequently licensed Structure's GLP-1 patents for $100M upfront. Roche is both a strategic counterparty and a competitive oral GLP-1 developer, making it a uniquely adjacent peer.
• Novo Nordisk: Novo Nordisk pioneered the GLP-1 category with semaglutide (Wegovy/Ozempic) and is advancing oral semaglutide formulations. As the established market leader with deep physician relationships, payer contracts, and global manufacturing, Novo represents both the incumbent benchmark and the most direct threat to Structure's oral obesity positioning.

Emerging players

• Metsera: Metsera was an emerging obesity biotech (recently acquired by Pfizer for ~$10B) developing next-generation injectable and oral peptide obesity therapeutics. Metsera's positioning as an emerging oral/injectable obesity player with significant exit value provides a useful precedent for Structure's strategic trajectory.
• Keros Therapeutics: Keros Therapeutics is a clinical-stage biotech developing therapeutics targeting TGF-beta superfamily and related pathways, with emerging activity in metabolic disease. While focused on different molecular targets, Keros is comparable to Structure as a similarly-sized mid-cap clinical-stage biotech with platform-driven pipeline expansion.

Others

• Schrödinger: Schrödinger is a computational chemistry and molecular simulation company that co-founded Structure Therapeutics and holds ~6% equity. While not a direct therapeutic competitor, Schrödinger's platform powers Structure's structure-based drug design and represents the underlying enabling technology relationship.

Regional players

• Innovent Biologics: Innovent is a leading Chinese biopharmaceutical company developing mazdutide, a GLP-1/glucagon dual agonist, primarily for the Chinese market. As a regional obesity player with a multi-mechanism approach, Innovent is comparable to Structure in targeting next-generation obesity mechanisms outside the US/EU.
• Sciwind Biosciences: Sciwind Biosciences is a Chinese clinical-stage biotech developing oral peptide formulations of semaglutide for the Chinese market. Sciwind's focus on oral GLP-1 obesity therapeutics makes it thematically comparable to Structure's oral approach, though its regional focus limits direct US/EU overlap.

Market position

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/structure-therapeutics
• Xx.com/StructureTx

Revenue estimate

Valuation estimate

Number of profiles

Profiles16 records

Subsidiaries1 record

Funding overview

Funding rounds8 records

Investors23 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Structure Therapeutics